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Section 121 of the 1997 FDA Modernization Act
(FDAMA) required that PET drugs be prepared according
to U.S. Pharmacopeia (USP) compounding standards and
PET drug monographs until the Food and Drug Adminis-
tration (FDA) established appropriate approval processes
and good manufacturing practice (GMP) regulations spe-
cific to these drug products. With the FDA’s final enactment
of its FDAMA commitments on June 12, 2012, the provi-
sions of section 121 are no longer in effect. This created an
unprecedented situation wherein a long-standing regulatory
pathway for PET drugs was eliminated. The objectives of
this article are 3-fold: to describe FDAMA and the role of
USP monographs, to describe the impact of potential
changes to the role of USP monographs for PET drugs after
the sunset of FDAMA, and to describe recommendations
from the Society of Nuclear Medicine and Molecular Im-
aging (SNMMI) Committee on Pharmacopeia for the future
of USP monographs for PET drugs.
THE USP MONOGRAPHS AND FDAMA, SECTION 121
The USP is a compendium of drug quality standards. USP
drug standards (i.e., monographs) are typically developed after
FDA approval of the drug product for commercial marketing
and are based on information and data supplied to the USP
by the responsible pharmaceutical company. The U.S. FDA
recognizes the USP as an official compendium and may
enforce compliance with USP standards under the adulter-
ation and misbranding provisions of the Federal Food, Drug,
and Cosmetic Act. These provisions extend broad authority
to the FDA to prevent the marketing of drugs that do not
meet USP standards. Publication of a USP monograph for
a drug product does not mean, however, that all drug
products that meet USP standards are FDA-approved for
commercial marketing. Rather, the FDA approves marke-
ting applications from pharmaceutical companies or other
entities in the form of a New Drug Application (NDA) or
Abbreviated New Drug Application (ANDA) for the drug
product. Also, because the existence of a USP monograph
does not, by itself, confer FDA-approval status, reimburse-
ment decisions related to a drug product are not based on
whether a USP monograph is in place for that drug product.
Section 121 of FDAMA enabled the clinical use (i.e., use
for routine patient care) of PET drugs that were compounded
“in conformity with the PET compounding standards and the
official monographs of the United States Pharmacopoeia. . .”
until such time that the FDA established approval processes
and GMPs specific to PET drugs (1). Likewise, FDAMA
specified that the preparation of PET drugs being evaluated
or used under an Investigational New Drug (IND) applica-
tion (title 21 of Code of Federal Regulations part 312 [21
CFR 312]) or the Radioactive Drug Research Committee
(RDRC) regulatory pathway (21 CFR 361) must be in con-
formance with USP General Chapter ,823. (“PET Drugs
for Compounding, Investigational, and Research Uses”) and
the USP monograph for the PET drug, if such was in exis-
tence. In this manner, FDAMA established a unique role for
the USP compounding standards and monographs for PET
drugs in that USP criteria substituted for compliance with the
FDA’s standard drug approval processes and the FDA’s
GMP standards for traditional drug products (21 CFR 211).
With the FDA’s final enactment of its FDAMA commit-
ments on June 12, 2012, the provisions of section 121 of
FDAMA are no longer in effect. This created an unprecedented
situation wherein a long-standing regulatory pathway is now
eliminated for PET drugs. After this date:
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1. PET drugs intended for clinical use must be produced
according to a submitted NDA/ANDA and PET GMP
standards (21 CFR 212). This applies to commercially
distributed PET drugs, as well as to those prepared at
medical institutions for internal use.
2. Nonapproved PET drugs intended for clinical re-
search purposes must be prepared in accordance with
the PET GMPs or with USP General Chapter ,823..
In addition, these PET drugs must be subject to either
approval by an RDRC (21 CFR 361) or FDA accep-
tance of an IND application (21 CFR 312). Note that
clinical research studies directed at using or evaluat-
ing FDA-approved PET drugs for off-label indica-
tions may or may not be subject to the submission
of an IND application (see IND exemption criteria
at 21 CFR 312.2).
USP General Chapter ,823. requires compliance with
USP standards if a USP monograph exists for a PET drug;
however, a monograph is not a requirement for the produc-
tion of a PET drug under this USP General Chapter. In
addition, a USP monograph is not required for PET drugs
produced under an approved NDA/ANDA or under evalu-
ation according to an FDA-accepted IND application. Since
the regulatory approval pathways for PET drugs in the post-
FDAMA era are independent of the existence of a USP
monograph, a reevaluation of the role of USP monographs
for these drugs is warranted.
THE USP MONOGRAPH PROCESS AND ITS FUTURE
APPLICATION TO PET DRUGS
As previously stated, the USP is a compendium of drug
standards (i.e., monographs). USP monographs are typically
developed some time after FDA approval of the drug product
for commercial marketing. The monographs are routinely
sponsored by the pharmaceutical company in possession of an
approved NDA or ANDA for the product of interest. The
sponsor provides supporting data from its approved applica-
tion, including method validation data for the analytic
methods used for the drug product. This information is
necessary either to create a new monograph or to revise an
existing monograph. The sponsor also provides samples of the
appropriate reference standards to the USP to support the
analytic methods used for the drug. The USP scientific staff
and expert volunteers review the information from the
sponsor, conduct laboratory tests if necessary, and publish
the new or revised monograph in the Pharmacopeial Forum
for public comment. On the basis of the comments received
through the Pharmacopeial Forum, the USP staff and expert
volunteers take appropriate action to finalize the monograph.
In this manner, the information from the sponsor and public
comments provide the foundation for the standards that appear
in USP monographs. The USP Web site (www.usp.org)
describes the monograph development process in more detail.
During the early evolution of PET and before the in-
volvement of the FDA, there were no public standards for
the preparation (i.e., compounding) of PET drugs that were
used for clinical or research purposes. This lack led the
USP to develop PET drug compounding standards and
monographs. The first USP monograph for a PET drug was
published in 1989 (2). This monograph described quality
standards and analytic methods for 18F-fludeoxyglucose in-
jection. More monographs were published for various PET
drugs throughout the 1990s, and the total number of USP
monographs for PET drugs now stands at 12. The quality
standards and analytic methods included in these mono-
graphs were provided to the USP by various academic
sponsors. The supporting data for these monographs may
not have included suitable validation data to support the
analytic methods. In addition, reference standards may not
have been provided to the USP. Of the 12 PET drugs with
a USP monograph, 8 have limited commercial application
and are not currently described in an approved NDA or
ANDA. These products are described in Table 1. The remain-
ing 4 PET drugs with a USP monograph have been commer-
cially distributed and are described in an approved NDA or
ANDA. These products, approvals, and sponsors are described
in Table 2. The USP will work directly with the NDA and
ANDA sponsors to manage USP monographs for the products
listed in Table 2. Since this is a typical process for the USP, it
will not be discussed further.
With the sunset of the provisions in section 121 of
FDAMA, the PET community must consider changes to
the role of USP monographs for the non–FDA-approved
PET drugs listed in Table 1. These considerations must
address the fact that method validation data and reference
standards may not exist for some of the PET drug mono-
graphs. In some cases, the analytic method may even be
outdated or may use chromatographic columns that are
no longer commercially available. There are 3 potential
approaches for managing the future of these PET drug
monographs.
The first approach is to leave the USP monographs for
the PET drugs listed in Table 1 as they are currently
written. Compared with traditional drug products, this
creates the unusual situation wherein USP monographs
exist for drugs that are not FDA-approved. For PET drugs
prepared in accordance with USP General Chapter
TABLE 1
PET Drugs with a USP Monograph but
Not Approved by the FDA
PET drug
18F-fluorodopa injection
11C-flumazenil injection
11C-methionine injection
11C-raclopride injection
11C-sodium acetate injection
11C-carbon monoxide injection
11C-mespiperone injection
15O-water injection
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,823., compliance with the respective USP monograph
would be required for those PET drugs with a USP mono-
graph. If it is not possible to comply with an existing USP
monograph, institutions involved in approving the re-
spective clinical investigation under the authority of an
RDRC (21 CFR 361) would be required to submit an IND
application. Under an IND application, the FDA may
exert enforcement discretion with regard to whether com-
pliance with the USP monograph is required. However,
RDRCs do not have the authority to exert such enforce-
ment discretion. Thus, the existence of USP monographs
for nonapproved PET drugs limits the flexibility of RDRCs
regarding production processes and analytic methods for
these PET drugs and can place restrictions on the RDRC’s
ability to approve a clinical investigation. In addition, since
reference standards may not exist and the analytic methods
may not be validated for some PET drug monographs, the
potential exists for erroneous analytic methods. For these
reasons, the do-nothing scenario does not seem to be a viable
option.
The second approach is to revise the USP monographs in
Table 1. The revision process would address the develop-
ment of appropriate validation data and the correction of
erroneous or obsolete methods. The development of the
appropriate reference standards should also be included in
the revision process for these monographs. Similar to the
first approach, this approach perpetuates the current, non-
standard situation in which USP monographs exist for drugs
that are not FDA-approved and limits the flexibility of
RDRCs and IND holders. The second approach requires
a sponsor (or group of sponsors) from the PET community
who must petition the USP to begin the revision process
and provide the required data and reference standards to
support the revision. The sponsor (or group of sponsors)
would also be required to maintain the monograph on an
ongoing basis in the event of future changes necessitated
by new regulations, USP requirements, or obsolescence.
USP would maintain the monographs in Table 1 as official,
enforceable monographs.
The third approach is to eliminate the existing mono-
graphs for the PET drugs listed in Table 1. In this case, the
USP would maintain monographs only for PET drugs that
are FDA-approved. This approach provides RDRCs and
IND holders with more flexibility for the PET drugs listed
in Table 1 since production processes and analytic methods
may be described and justified in the IND or RDRC appli-
cation, eliminating the need to follow prescribed methods
in the USP. Institutions would be required to develop method
validation data to support their IND or RDRC applications,
but validation data at early development stages is typically
less rigorous than that required for FDA-approved products
(3,4). The third approach does not require the identification
of a sponsor (or group of sponsors) from the PET community
to support the monographs for the PET drugs in Table 1.
Finally, this approach places the PET monographs in a posi-
tion consistent with monographs for traditional drugs. To
achieve this approach, the PET community must petition the
USP to eliminate the monographs in Table 1. In the future, if
a sponsor is interested in gaining FDA approval of a drug in
Table 1 with a deleted monograph, a new monograph for that
drug could be developed and submitted to the USP pursuant
to existing monograph submission guidelines.
Regardless of the scenario adopted for the PET drug
monographs in Table 1, it is clear that the submission of
new or revised monographs for PET drugs in the post-FDAMA
era must be in accordance with current USP requirements,
including the submission of the appropriate reference stan-
dards and validation data for analytic methods (e.g., accu-
racy, precision, sensitivity, and linearity) (5).
USP MONOGRAPHS AND REIMBURSEMENT FOR
INVESTIGATIONAL PET DRUGS
The change in the regulatory status of the PET drugs in
Table 1 may also have implications in limited instances in
which imaging procedures that use these products are re-
imbursed. Medicare reimbursement for all PET drugs is
limited under the national exclusionary ruling by the Center
for Medicare and Medicaid Services. This applies to all
PET drugs before and after the sunset of section 121 of
FDAMA. Since the PET drugs in Table 1 could be used
for routine patient care before June 12, 2012, private payers
have reimbursed for some procedures associated with these
PET drugs. It is also possible that the USP monographs for
these PET drugs have played an important role in establish-
ing the safety of these products. The extent of the reim-
bursement for these products is not known.
TABLE 2
PET Drugs with a USP Monograph and an Approved NDA or ANDA (7)
PET Drug Application number Holder Approval date Current status
13N-ammonia injection NDA 22-119 Feinstein Institute August 23, 2007 Active
18F-fludeoxyglucose injection NDA 20-306 Downstate Clinical PET Center August 19, 1994 Discontinued
NDA 21-768 Weill Medical College August 4, 2004 Active
NDA 21-870 Feinstein Institute August 19, 2005 Active
ANDA 79-086 PETNET Solutions February 25, 2011 Active
18F-sodium fluoride injection NDA 17-042 GE Healthcare February 24, 1972 Discontinued
NDA 22-494 National Cancer Institute January 26, 2011 Discontinued
89Rb rubidium chloride injection NDA 19-414 Bracco December 29, 1989 Active
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As of June 12, 2012, the PET drugs in Table 1 cannot
continue to be applied for traditional clinical uses because
NDAs or ANDAs do not exist for these products. Instead,
these PET drugs are now subject to either an RDRC or an
IND. This created an unusual situation wherein PET drugs
that have been used clinically (and may have been reim-
bursed by private payers) are now categorized as “research”
or “investigational.” The FDA has recognized this situation
and responded with the publication of a guidance document
describing the use of expanded-access INDs to allow the
continued clinical use of the PET drugs in Table 1 (6). It is
possible that private payers may continue to reimburse for
expanded-access IND drugs. To date, the presence of a USP
monograph for the PET drug has been used as one basis for
a payment decision (Denise Merlino, oral communication,
August 2012). If the USP would remove the outdated mono-
graphs to an “Omitted Monograph” category, including the
date of removal, payers might still be able to access the
Omitted Monograph and could continue to use it as a basis
for a payment decision.
RECOMMENDATION of SNMMI COMMITTEE
ON PHARMACOPEIA
The SNMMI Committee on Pharmacopeia recommends
that the existing USP monographs for PET drugs listed
in Table 1 should be eliminated or moved to an Omitted
Monograph status. These recommendations are based on the
following considerations:
• This approach is consistent with the development of
USP monographs for traditional drug products.
• The current USP monographs for these PET drugs may
incorporate analytic methods that have not been suit-
ably validated or may no longer be viable to perform.
• Compliance with the current USP monographs for
these PET drugs places certain limitations on the prep-
aration of these agents. The inability to comply with
these USP monographs can restrict the ability to ap-
prove respective clinical investigations under the RDRC
(21 CFR 361) approval process.
• Revision of the current USP monographs for the non-
approved PET drugs requires the active initial and
continuing involvement of members of the PET
community. Such active involvement has historically
not been forthcoming.
• For PET drugs listed in Table 1, any interested individ-
ual or group can sponsor revision (including supporting
validation data and standards) and provide maintenance
of the monograph.
• The Committee recommends that development of fu-
ture USP monographs for PET drugs should be lim-
ited to those drugs described in an FDA-approved
NDA.
The SNMMI Committee on Pharmacopeia is actively
seeking input from the PET community regarding current
and future USP monographs for PET drugs. Anyone
interested in commenting can visit the USP Key Issue
page at http://www.usp.org/usp-nf/key-issues/usp-nf-general-
chapter-823. All comments will be considered before taking
any formal action related to the current USP monographs.
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